Protective Immunity
保护性免疫
基本信息
- 批准号:8307106
- 负责人:
- 金额:$ 51.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS vaccine developmentAcuteAdenovirusesAnimalsChronic PhaseCytomegalovirusElectroporationFlavivirusGaggingGenesHIVHIV vaccineHumanImmune responseImmunityInstitutesInstructionIntentionInterleukin-12LifeMacacaMacaca mulattaMonkeysOpen Reading FramesOutcomePlasmidsProteinsProteomeRecombinant DNARecombinantsSIVSerotypingT cell responseTestingVaccinatedVaccinationVaccine DesignVaccinesViralVirusYellow FeverYellow Fever Vaccinedesignimprovednonhuman primatenovel vaccinespreventresearch studyvector
项目摘要
We hypothesize that a recombinant yellow fever vaccine (rYF) or rDNA (delivered by electroporation along
with IL-12; EP+IL-12) prime followed by a recombinant adenovirus serotype 35 (rAd35) boost can control
viral replication after either a homologous or heterologous AIDS virus challenge. We plan to test this
hypothesis in macaques using rigorous challenges with the highly pathogenic SIV isolates, SIVmac251 and
SIVsmE660. In a previous study, we found that a rDNA prime followed by a rAd5 boost (encoding all of the
SIVmac239 proteins except for Env) reduced acute and chronic phase replication after a pathogenic
SIVsmE660 mucosal challenge in six of eight vaccinated Indian rhesus macaques. Indeed, six of the
vaccinees have no detectable viral replication at one year post challenge. This positive outcome is
exceedingly rare in vaccine experiments using a pathogenic SIV challenge. We also discovered that vaccineinduced
T cell responses against Gag and Vif correlated with this good outcome. We postulate that there are
additional targets in the SIV proteome that can induce efficacious T cell responses. More recently our
colleagues at lAVI have shown that vaccination with rDNA plasmids encoding all of the SIV proteins
(including Env) by EP along with a plasmid encoding IL-12, followed by a rAd5 boost reduced viral replication
of the highly pathogenic SIVmac239 challenge virus in seven of eight macaques. Indeed these vaccine
results, along with the recent findings of Louis Picker using recombinant rhesus cytomegalovirus (rhCMV)
vectors are the most encouraging non-human primate vaccine results to date. Our intention now is to
perform a vaccine study to determine which of the SIV proteins are important targets for the control of viral
replication in our first specific aim. In an attempt to improve upon these last two experiments we will also
include newly discovered cryptic open reading frames (cORFs) in the vaccine. Our second specific aim is to
determine whether a rYF or rDNA (EP+IL-12) prime followed by a rAd35 boost can control viral replication
after either a homologous or heterologous AIDS virus challenge.
我们假设重组黄热病疫苗(rYF)或rDNA(通过电穿孔递送)可以在免疫系统中进行
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David I Watkins其他文献
HIV pathogenesis: the first cut is the deepest
艾滋病病毒发病机制:初次感染影响最为深远
- DOI:
10.1038/ni0505-430 - 发表时间:
2005-05-01 - 期刊:
- 影响因子:27.600
- 作者:
Louis J Picker;David I Watkins - 通讯作者:
David I Watkins
David I Watkins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David I Watkins', 18)}}的其他基金
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
借鉴埃博拉病毒的成功经验:单克隆抗体也能拯救黄热病感染后的生命吗?
- 批准号:
10422995 - 财政年份:2021
- 资助金额:
$ 51.45万 - 项目类别:
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
借鉴埃博拉病毒的成功经验:单克隆抗体也能拯救黄热病感染后的生命吗?
- 批准号:
10669613 - 财政年份:2021
- 资助金额:
$ 51.45万 - 项目类别:
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
借鉴埃博拉病毒的成功经验:单克隆抗体也能拯救黄热病感染后的生命吗?
- 批准号:
10463875 - 财政年份:2021
- 资助金额:
$ 51.45万 - 项目类别:
Can vaccine-induced CD8 T cells prevent chronic phase AIDS virus replication?
疫苗诱导的 CD8 T 细胞能否阻止慢性期艾滋病病毒复制?
- 批准号:
8787712 - 财政年份:2014
- 资助金额:
$ 51.45万 - 项目类别:
Can vaccine-induced CD8 T cells prevent chronic phase AIDS virus replication?
疫苗诱导的 CD8 T 细胞能否阻止慢性期艾滋病病毒复制?
- 批准号:
8976140 - 财政年份:2014
- 资助金额:
$ 51.45万 - 项目类别:
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development
黄热病、rDNA (EP IL-12) 和 rAd35 作为艾滋病疫苗开发的载体
- 批准号:
8497605 - 财政年份:2012
- 资助金额:
$ 51.45万 - 项目类别:
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development
黄热病、rDNA (EP IL-12) 和 rAd35 作为艾滋病疫苗开发的载体
- 批准号:
8688135 - 财政年份:2012
- 资助金额:
$ 51.45万 - 项目类别:
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development
黄热病、rDNA (EP IL-12) 和 rAd35 作为艾滋病疫苗开发的载体
- 批准号:
8301117 - 财政年份:2012
- 资助金额:
$ 51.45万 - 项目类别:
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development
黄热病、rDNA (EP IL-12) 和 rAd35 作为艾滋病疫苗开发的载体
- 批准号:
8874851 - 财政年份:2012
- 资助金额:
$ 51.45万 - 项目类别:
DEVELOPMENT OF IMMUNE MONITORING REAGENTS AND MHC TYPING TECHNOLOGIES
免疫监测试剂和MHC分型技术的开发
- 批准号:
8358206 - 财政年份:2011
- 资助金额:
$ 51.45万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 51.45万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 51.45万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 51.45万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 51.45万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 51.45万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 51.45万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 51.45万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 51.45万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 51.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 51.45万 - 项目类别:
Operating Grants














{{item.name}}会员




